Oct 12 (Reuters) - Moderna Inc MRNA.O:
MODERNA: PRESENTS PROMISING EARLY DATA FOR INVESTIGATIONAL CANCER ANTIGEN THERAPY
MODERNA: MRNA-4359 IN COMBINATION WITH PEMBROLIZUMAB SHOWED CONSISTENTLY MANAGEABLE SAFETY PROFILE, NO NEW IMMUNE-RELATED ADVERSE EVENTS
MODERNA: MRNA-4359 HAS ADVANCED INTO PHASE 2 PORTION OF ONGOING PHASE 1/2 TRIAL
Source text: [ID:]